Sree Kant, BAKX Therapeutics CEO
November 18, 2021 10:53 AM EST
Financing

Months af­ter mas­sive Ipsen deal, BAKX Ther­a­peu­tics nets more cash for its 'Thel­ma and Louise' ap­proach to can­cer cell death

Nicole DeFeudis

Editor

BAKX Ther­a­peu­tics emerged from stealth in a big way back in Ju­ly, strik­ing an $852 mil­lion deal with Ipsen for its lead can­cer can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times